Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
AURA logo AURA
Upturn stock ratingUpturn stock rating
AURA logo

Aura Biosciences Inc (AURA)

Upturn stock ratingUpturn stock rating
$6.43
Last Close (24-hour delay)
Profit since last BUY-8.14%
upturn advisory
SELL
SELL since 1 day
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: AURA (1-star) is a SELL. SELL since 1 days. Profits (-8.14%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $21

1 Year Target Price $21

Analysts Price Target For last 52 week
$21 Target price
52w Low $4.34
Current$6.43
52w High $12.38

Analysis of Past Performance

Type Stock
Historic Profit -53.56%
Avg. Invested days 19
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 399.43M USD
Price to earnings Ratio -
1Y Target Price 21
Price to earnings Ratio -
1Y Target Price 21
Volume (30-day avg) 7
Beta 0.46
52 Weeks Range 4.34 - 12.38
Updated Date 08/29/2025
52 Weeks Range 4.34 - 12.38
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.95

Earnings Date

Report Date 2025-08-13
When -
Estimate -0.47
Actual -0.47

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -32.14%
Return on Equity (TTM) -55.39%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 240231783
Price to Sales(TTM) -
Enterprise Value 240231783
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -5.68
Shares Outstanding 62119900
Shares Floating 35257998
Shares Outstanding 62119900
Shares Floating 35257998
Percent Insiders 1.98
Percent Institutions 84.55

ai summary icon Upturn AI SWOT

Aura Biosciences Inc

stock logo

Company Overview

overview logo History and Background

Aura Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies to treat life- and vision-threatening cancers. Founded in 2009, Aura is pioneering the development of virus-like drug conjugates (VDCs) for targeted delivery of therapies to tumors. Significant milestones include advancing its lead product candidate, AU-011 (belzupacap sarotalocan), into clinical trials for the treatment of choroidal melanoma and securing funding through venture capital and an IPO.

business area logo Core Business Areas

  • Oncology Therapeutics: Develops virus-like drug conjugates (VDCs) for the targeted destruction of cancer cells.
  • Choroidal Melanoma Treatment: Focuses on developing AU-011 for the first-line treatment of primary choroidal melanoma, a rare and life-threatening eye cancer.

leadership logo Leadership and Structure

Elisabet de los Pinos, PhD, is the President and CEO. The company has a management team overseeing research and development, clinical operations, and business development. The board of directors includes representatives from venture capital firms and industry experts.

Top Products and Market Share

overview logo Key Offerings

  • AU-011 (belzupacap sarotalocan): A virus-like drug conjugate (VDC) designed to selectively bind to and destroy cancer cells in the eye. Currently in Phase 3 clinical trials for choroidal melanoma. Competitors are limited due to the novel approach, but traditional treatments include radiation therapy and enucleation. Market share is not yet applicable as the product is not yet commercialized. Revenue is currently $0.

Market Dynamics

industry overview logo Industry Overview

The oncology therapeutics market is large and growing, with a focus on targeted therapies and immunotherapies. The specific market for choroidal melanoma treatment is relatively small but underserved, with significant unmet medical needs.

Positioning

Aura Biosciences is positioned as an innovator in targeted cancer therapy, specifically in ocular oncology. Its VDC technology offers a potential advantage over traditional treatments by selectively destroying cancer cells while preserving vision.

Total Addressable Market (TAM)

The total addressable market for choroidal melanoma treatment is estimated to be in the hundreds of millions of dollars annually. With successful Phase 3 trials and commercialization, Aura could capture a significant portion of this market. Other oncology applications for the VDC platform significantly expand the TAM.

Upturn SWOT Analysis

Strengths

  • Novel VDC technology platform
  • Targeted approach to cancer treatment
  • First-in-class potential for AU-011
  • Experienced management team
  • Orphan drug designation for choroidal melanoma

Weaknesses

  • Clinical trial risk
  • Dependence on a single lead product candidate
  • Need for regulatory approval
  • Competition from established oncology therapies
  • Limited commercialization experience

Opportunities

  • Expansion of VDC platform to other cancers
  • Potential for partnerships with larger pharmaceutical companies
  • Favorable regulatory environment for orphan drugs
  • Growing demand for targeted cancer therapies
  • Positive clinical trial results

Threats

  • Clinical trial failures
  • Regulatory setbacks
  • Competition from other emerging therapies
  • Patent challenges
  • Market access and pricing pressures

Competitors and Market Share

competitor logo Key Competitors

  • LLY
  • NVS
  • MRK

Competitive Landscape

Aura Biosciences competes with established pharmaceutical companies that offer traditional cancer treatments. Its advantage lies in its novel VDC technology and targeted approach, but it faces challenges in terms of commercialization and market access. Aura Biosciences does not yet have a share of the Chroidal Melanoma market.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is limited due to the company being in the clinical stage. Growth is primarily reflected in R&D progress and pipeline development.

Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approval for AU-011. Analyst estimates vary widely based on the perceived probability of success. Revenue projected to increase significantly post commercialization.

Recent Initiatives: Recent initiatives include advancing AU-011 through Phase 3 clinical trials, expanding the VDC platform to other oncology targets, and securing partnerships for manufacturing and distribution.

Summary

Aura Biosciences is a clinical-stage company with a novel technology for targeted cancer therapy and a promising lead candidate, AU-011. The company faces significant clinical and regulatory risks, but it has the potential to disrupt the treatment of choroidal melanoma. Its success depends on favorable clinical trial results, regulatory approval, and effective commercialization. Investors should be aware of the high-risk, high-reward nature of this investment.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (SEC)
  • Company website
  • Analyst reports
  • ClinicalTrials.gov

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on available data and is subject to change. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Aura Biosciences Inc

Exchange NASDAQ
Headquaters Boston, MA, United States
IPO Launch date 2021-10-29
Founder, CEO, President & Director Dr. Elisabet de los Pinos Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 106
Full time employees 106

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmette"guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.